RhumbLine Advisers
NMRA icon

RhumbLine Advisers’s Neumora Therapeutics NMRA Stock Holding History

RhumbLine Advisers’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$132K Buy
77,566
+74,985
+2,905% +$143K ﹤0.01% 3437
2026
Q1 		$5.03K Hold
2,581
– – ﹤0.01% 3881
2025
Q4 		$4.62K Hold
2,581
– – ﹤0.01% 3929
2025
Q3 		$4.7K Hold
2,581
– – ﹤0.01% 3921
2025
Q2 		$1.89K Sell
2,581
-111,877
-98% -$84.8K ﹤0.01% 4001
2025
Q1 		$114K Buy
114,458
+1,718
+2% +$2.94K ﹤0.01% 3344
2024
Q4 		$1.2M Buy
112,740
+1,075
+1% +$12.9K ﹤0.01% 2155
2024
Q3 		$1.48M Buy
111,665
+8,407
+8% +$98.1K ﹤0.01% 2059
2024
Q2 		$1.02M Buy
103,258
+85,706
+488% +$887K ﹤0.01% 2236
2024
Q1 		$241K Buy
17,552
+1,832
+12% +$29.6K ﹤0.01% 3087
2023
Q4 		$268K Buy
+15,720
New +$193K ﹤0.01% 3036

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RhumbLine Advisers's NMRA Position: Q2 2026 in Review

RhumbLine Advisers increased its Neumora Therapeutics (NMRA) stake by 2,905% in Q2 2026, buying an estimated $143K and bringing the position to 77,566 shares worth $132K. The position accounts for ﹤0.01% of the portfolio, ranked #3437.

RhumbLine Advisers first reported a position in NMRA in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.48M in Q3 2024. 75 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • RhumbLine Advisers held 77,566 shares of Neumora Therapeutics worth $132K as of Q2 2026.
  • RhumbLine Advisers bought 74,985 Neumora Therapeutics shares in Q2 2026, an estimated $143K.
  • Neumora Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3437 holding.
  • RhumbLine Advisers first reported a position in Neumora Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • RhumbLine Advisers's Neumora Therapeutics position peaked at $1.48M in Q3 2024.
  • 75 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.